Literature DB >> 2273487

Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis.

L L Dupuis1, G Koren, A Shore, E D Silverman, R M Laxer.   

Abstract

In order to assess the interaction between methotrexate (MTX) and nonsteroidal antiinflammatory drugs (NSAID), we studied the pharmacokinetics of oral MTX alone and in the presence of the usually prescribed NSAID in 7 children with chronic arthritis. The NSAID studied included tolmetin, indomethacin, naproxen, and aspirin. Six patients were treated with multiple NSAID. The mean MTX elimination half-life was prolonged when NSAID were coadministered (1.7 +/- 0.5 vs 1.2 +/- 0.1 h; p = 0.03). However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID. Although the differences between the mean Cl and Auc were not statistically significant, a wide variation in the impact of NSAID on MTX Cl was observed. In 6 of 7 patients, the Auc increased during NSAID administration from 19 to 140%. This degree of increase may be clinically significant in some individuals. It is consequently recommended to closely monitor patients who are receiving MTX and NSAID for MTX toxicity until these results can be verified in a larger population.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2273487

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  15 in total

Review 1.  Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol.

Authors:  C Litalien; E Jacqz-Aigrain
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

2.  Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.

Authors:  P K Honig; B K Gillespie
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.

Authors:  B Bannwarth; F Péhourcq; T Schaeverbeke; J Dehais
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

Review 4.  Nonsteroidal anti-inflammatory drugs. Differential use in older patients.

Authors:  L Girgis; P Brooks
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

Review 5.  Drug interactions between prescribed and over-the-counter medication.

Authors:  P K Honig; B K Gillespie
Journal:  Drug Saf       Date:  1995-11       Impact factor: 5.606

6.  Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria.

Authors:  Tim Niehues; Gerd Horneff; Hartmut Michels; Michaela Sailer Höck; Lothar Schuchmann
Journal:  Rheumatol Int       Date:  2005-02-02       Impact factor: 2.631

7.  The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis.

Authors:  C Godfrey; K Sweeney; K Miller; R Hamilton; J Kremer
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

Review 8.  Adverse drug interactions with nonsteroidal anti-inflammatory drugs (NSAIDs). Recognition, management and avoidance.

Authors:  A G Johnson; P Seideman; R O Day
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

Review 9.  Methotrexate in juvenile rheumatoid arthritis. Do the benefits outweigh the risks?

Authors:  E H Giannini; J T Cassidy
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

Review 10.  Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan.

Authors:  Masaaki Mori; Takuya Naruto; Tomoyuki Imagawa; Takuji Murata; Syuji Takei; Minako Tomiita; Yasuhiko Itoh; Satoshi Fujikawa; Shumpei Yokota
Journal:  Mod Rheumatol       Date:  2008-09-25       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.